Open Orphan

Sector:
Biotechnology
Exit:
Placement of blocks of shares on AIM

Open Orphan is a world leader in the testing of vaccines and antivirals using human challenge clinical trials.

In October 2020, the company announced a contract with the UK Government to develop the world’s first human COVID-19 challenge study model. This, as well as a pipeline of non-COVID-19 related services, gave rise to an increased share price.